

UNCLASSIFIED//

ROUTINE

R 171847Z NOV 20 MID200000387405U

FM SECNAV WASHINGTON DC

TO ALNAV

INFO SECNAV WASHINGTON DC
CNO WASHINGTON DC
CMC WASHINGTON DC

BT
UNCLAS

ALNAV 096/20

MSGID/GENADMIN/SECNAV WASHINGTON DC/-/NOV//

SUBJ/NAVY MEDICINE COVID-19 RETURN TO FLIGHT DUTY STATUS GUIDELINE POLICY IN
RESPONSE TO THE CORONAVIRUS DISEASE 2019//

REF/A/DOC/CNAF/05MAY16//
REF/B/DOC/BUMED/15FEB19//
REF/C/DOC/NAMI ARWG/NMOTC/27APR20//

NARR/REF A IS THE CNAF M-3710, NATOPS GENERAL FLIGHT AND OPERATING
INSTRUCTIONS MANUAL, CHAPTER 8 AEROMEDICAL AND SURVIVAL.
REF B IS THE NAVMED P-117, MANUAL OF THE MEDICAL DEPARTMENT, CHAPTER 15
MEDICAL EXAMINATIONS.
REF C IS THE NAVAL AEROSPACE MEDICAL INSTITUTE, AEROMEDICAL REFERENCE AND
WAIVER GUIDE.//

RMKS/1. This ALNAV announces Navy Medicine's COVID-19 Return to Flight Duty
Status Guideline in response to the Coronavirus Disease 2019 (COVID-19).
This policy applies to all Navy and Marine Corps personnel requiring a Class
1 or Class 2 Special Duty Medical Examination for flight duty status as
required in reference (a) and defined in reference (b). Naval aircrew who
have been exposed to COVID-19, tested positive for COVID-19, or infected with
COVID-19 will require a defined evaluation, per reference (c), to return to
flight duty status. The Navy Medicine COVID-19 Return to Flight Duty Status
Guideline is contained in reference (c), Respiratory section:
[https://www.med.navy.mil/sites/nmotc/nami/arwg/pages/
aeromedicalreferenceandwaiverguide.aspx](https://www.med.navy.mil/sites/nmotc/nami/arwg/pages/aeromedicalreferenceandwaiverguide.aspx).

2. To support the medical readiness of the armed forces, Navy Medicine
Readiness and Training Command, Commanders and Commanding Officers, and Navy
Medicine Readiness and Training Unit Officers-in-Charge shall provide for
expedited medical evaluations, referrals, laboratory services,
electrocardiograms, pulmonary function tests (PFT), exercise tolerance
testing (ETT), and Naval Aerospace Medicine Institute (NAMI) submissions.
Expedited consults, ETT, and PFT are defined as performed and completed
within seven business days from the time of the consult or order. These
consults and tests will not require pre-appointment COVID-19 testing if
patient has met the Centers for Disease Control and Prevention recovery

criteria and it is less than 90 days from date of symptom onset.

3. NAMI will conduct submission review within two business working days for completed submissions that require NAMI duty disposition per reference (c). Contact NAMI when submitting a post-COVID-19 evaluation to fast track the review. NAMI Physical Expedite Request Email: usn.pensacola.navmedotcnafl.list.nami-physqualtech(@)mail.mil. Aerospace Medicine providers who conduct a return to flight duty status evaluation on aircrew who had a symptomatic case of COVID-19 shall report each evaluation to the aircrew's Type Commander Force Surgeon, Marine Air Wing Surgeon, or if outside those administrative controls to the Bureau of Medicine and Surgery, Branch Head, Aerospace Medicine Programs.

4. All commands with personnel who are required to have a Class 1 or Class 2 Aeromedical Examination to be in a Special Duty Flight Status, with personnel who perform Aeromedical Examinations, and with personnel who provide medical care for naval aircrew will execute and distribute this policy.

5. Per reference (c), this ALNAV applies to all civilian and uniformed military Navy and Marine Corps personnel required to meet Class 1 and Class 2 aeromedical physical standards to continue in their Special Duty Flight Status.

6. The primary point of contact for this message is CDR Roy Allen Hoffman, roy.a.hoffman.mil(@)mail.mil, (703) 681-9323.

7. Released by the Honorable Kenneth J. Braithwaite, Secretary of the Navy.

BT

#0001

NNNN

UNCLASSIFIED//